ROYALTY PHARMA PLC news, videos and press releases
For more news please use our advanced search feature.
ROYALTY PHARMA PLC - More news...
ROYALTY PHARMA PLC - More news...
- Royalty Pharma Announces Upcoming Investor Day
- Royalty Pharma to Present at TD Cowen’s 45th Annual Health Care Conference
- Royalty Pharma Announces R&D Funding Collaboration With Biogen
- Royalty Pharma Reports Q4 and Full Year 2024 Results
- Royalty Pharma Announces Sale of MorphoSys Development Funding Bonds
- Royalty Pharma to Announce Fourth Quarter and Full Year 2024 Financial Results on February 11, 2025
- Royalty Pharma to Highlight Accomplishments and Provide Business Update at 43rd Annual J.P. Morgan Healthcare Conference
- Royalty Pharma Announces Transformative Step in Company’s Evolution With Acquisition of its External Manager and $3 Billion Share Repurchase Program
- Royalty Pharma Announces Dividend Increase
- Royalty Pharma to Present at Upcoming Investor Conferences
- Royalty Pharma Announces Inaugural Prize for Impact in Healthcare
- Royalty Pharma to Acquire Royalty Interest in Geron’s RYTELO for $125 Million
- Royalty Pharma Reports Third Quarter 2024 Results
- Royalty Pharma and Syndax Pharmaceuticals Enter Into $350 Million Royalty Funding Agreement for Niktimvo
- Royalty Pharma to Announce Third Quarter 2024 Financial Results on November 6, 2024
- Royalty Pharma Declares Fourth Quarter 2024 Dividend
- Royalty Pharma and Ascendis Pharma Enter Into $150 Million Royalty Funding Agreement
- Royalty Pharma to Present at Morgan Stanley’s 22nd Annual Global Healthcare Conference
- Royalty Pharma Reports Second Quarter 2024 Results
- Royalty Pharma Appoints Molly Sawaya as Executive Vice President, Head of Human Capital
- Royalty Pharma to Announce Second Quarter 2024 Financial Results on August 8, 2024
- Royalty Pharma Declares Third Quarter 2024 Dividend
- Royalty Pharma to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
- Royalty Pharma Announces Pricing of $1.5 Billion of Senior Unsecured Notes
- Royalty Pharma and Agios Pharmaceuticals Enter Into Vorasidenib Royalty Agreement for $905 Million
- Royalty Pharma and Cytokinetics Announce Expanded Strategic Funding Collaboration Totaling Up to $575 Million to Support Commercial Launch of Aficamten and to Advance R&D Pipeline
- Royalty Pharma to Present at Upcoming Investor Conferences
- Royalty Pharma Reports First Quarter 2024 Results
- Royalty Pharma to Acquire Royalty Interest in Sanofi’s Frexalimab
- Royalty Pharma to Announce First Quarter 2024 Financial Results on May 9, 2024
